House lawmakers voted Wednesday to approve a bill that would let terminally ill patients request access to experimental drugs that are under consideration by the FDA and have undergone early-stage clinical trials. The "right-to-try" legislation now heads to the Senate, which unanimously passed a different version of the bill last year.
Legislation that would fund cost-sharing reduction payments for three years and provide states $30 billion to set up a reinsurance program was left out of the $1.3 trillion omnibus spending bill unveiled late Wednesday by congressional leaders. The spending deal, which would keep the federal government open through September, must be passed by Senate and House lawmakers by midnight Friday to avert a government shutdown.
Dr. Robert Redfield has been appointed to lead the CDC. A longtime AIDS researcher, Redfield is also a professor at the University of Maryland's School of Medicine and worked at the Walter Reed Army Institute of Research for two decades.
The reason for the withdrawal of training materials for housing providers on LGBT rights is because transgender people in shelters make some women uncomfortable, said Housing and Urban Development Secretary Ben Carson. He told a House subcommittee that HUD's general counsel is open to discussing the issue.
A study in The BMJ showed that patients with type 2 diabetes who used DPP-4 inhibitors had a 75% increased risk of developing inflammatory bowel disease, compared with those on other antidiabetic drugs. Researchers evaluated 141,170 patients and found an association between longer duration of DPP-4 inhibitors use and gradual increase in IBD risk, which peaked after three to four years.
Obese individuals with and without type 2 diabetes who received an intravenous infusion of 3.0 pmol/kg/min of native oxyntomodulin had significantly increased insulin secretory rates and blunted glycemic excursion during a graded glucose infusion, compared with those on placebo, according to a study in Diabetes. Researchers used a cohort of 24 overweight and obese patients with and without diabetes and found that those with diabetes on OXM and liraglutide showed comparable effects, including beta cell glucose responsiveness restoration, to that of nonobese individuals without diabetes.
Dutch researchers analyzed data on 10 adults with type 1 diabetes and found that a wearable biosensor and algorithm, designed to predict hypoglycemia and wirelessly transmit heart rate data to a mobile device, detected "clear patterns" of heart rate changes before 28 of the observed 39 events. Researchers, who presented the findings at the Endocrine Society's annual meeting, said they would continue to refine the algorithm.
While biosimilar uptake continues to accelerate in the UK and the rest of Europe, the situation is different in the US, where barriers such as slow regulatory action have hindered the market. For one drug alone, Britain's annual savings attributed to biosimilar use totaled $113 million, and the pace of market entries is expected to grow as patents expire.
University of South Florida researchers found that adding the beet compound betanin to a copper-bound beta-amyloid mixture resulted in up to 90% lower oxidation of 3,5 di-tert-butylcatechol, suggesting the possible suppression of peptide misfolding. The findings, presented at the American Chemical Society annual meeting, shows the potential of betanin "as an inhibitor of certain chemical reactions in the brain that are involved in the progression of Alzheimer's disease," said researcher Li-June Ming.
- Page 1